<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">More adverse events were observed with famitinib plus CCRT (Table 
 <xref rid="Tab2" ref-type="table">2</xref>). The majority of adverse events were grade 1 or 2. The five most frequent adverse events were leukopenia (100%), neutropenia (100%), anemia (100%), radiation mucositis (100%), and nausea and vomiting (85%). The five most frequent grade 3 or 4 adverse events were leukopenia (90%), neutropenia (55%), thrombopenia (20%), anaemia (20%) and radiation mucositis (20%). In addition, grade 1 or 2 hemorrhage occurred in 2 (10%) patients and no grade 3–4 haemorrhage was recorded. No grade 5 adverse event was reported. Two out of three patients receiving 12.5 mg cisplatin had DLTs; one patient suffered grade 4 neutropenia lasting more than 5 days, and the other patient suffered grade 3 neutropenia with fever. After cisplatin was reduced to 80 mg/m
 <sup>2</sup>, in the remaining patients, one patient had grade 4 thrombocytopenia and one patient had grade 3 hypertension while receiving 25 mg cisplatin. Grade 3 hearing impairment occurred in one patient; no other grade 3 or 4 late adverse events were reported (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).
</p>
